4:30 PM - 4:45 PM (PDT), Monday, June 13, 2022
NEXEL is a South Korean biotechnology company specializing in stem cell technology with two main pipelines: developing protein-based therapeutic candidates for fibrosis-related diseases and human iPSC-derived cells.
Our protein/Peptide therapy pipelines, NP-011 and NPT-0025, were designed by remodeling a protein found in embryonic stem cell secretomes. They are exciting pre-clinical stage candidates showing unprecedented anti-fibrotic activity by modulating the integrin pathways. NP-011 and NPT-0025 target NASH-Fibrosis and IPF, respectively.
NEXEL is a specialist in the differentiation of human iPSC, having successfully developed several off-the-shelf products such as cardiomyocytes, hepatocytes, and neurons. hiPSC-derived cells are proving to be an excellent in vitro model to potentially revolutionize preclinical drug toxicity testing, as evidenced by upcoming ICH guideline changes(S7B) with CiPA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Associate Manager
NEXEL Co., Ltd.